Rallybio Corporation
NASDAQ:RLYBBiotechnology
Healthcare
$15.52 +0.03%
+$0.01 today
- Market cap
- $83.56M
- Beta
- -0.88
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.37
52W Low $2.40High $17.57
Volume 0.04M
Average 0.25M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$29.81M
FY 2025 · Annual
Investing Cash Flow
$47.27M
FY 2025 · Annual
+41.1% YoYFinancing Cash Flow
$16,000.00
FY 2025 · Annual
-99.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.01M) | (66.65M) | (74.56M) | (57.78M) | (8.98M) |
| Depreciation & Amortization | 109K | 167K | 150K | 131K | 92K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.65M | 9.5M | 10.92M | 7.99M | 5.31M |
| Change in Working Capital | (3.78M) | (936K) | 4.28M | (258K) | (4.19M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (976K) | 487K | (99K) | (698K) | (152K) |
| Other Working Capital | (2.8M) | (1.42M) | 4.38M | 440K | (4.04M) |
| Other Non-Cash Items | 1.51M | 640K | (1.05M) | 627K | (22.05M) |
| Operating Cash Flow | (45.53M) | (57.28M) | (60.27M) | (49.28M) | (29.81M) |
| Capital Expenditures | (333K) | (54K) | (12K) | 0 | 0 |
| Acquisitions (Net) | (2M) | (300K) | (2.25M) | (2M) | 0 |
| Purchases of Investments | (2M) | (201.32M) | (110.66M) | (48.93M) | (17.7M) |
| Sales of Investments | 2M | 89.5M | 138.33M | 84.43M | 46.47M |
| Other Investing Activities | (2K) | 0 | 2.25M | 0 | 18.5M |
| Investing Cash Flow | (2.33M) | (112.17M) | 27.66M | 33.49M | 47.27M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 86.2M | 51.53M | 143K | 5.41M | 16K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.23M) | (455K) | 0 | (206K) | 0 |
| Financing Cash Flow | 82.97M | 51.08M | 143K | 5.2M | 16K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.1M | (118.38M) | (32.46M) | (10.59M) | 17.47M |
| Free Cash Flow | (45.87M) | (57.34M) | (60.28M) | (49.28M) | (29.81M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$9.0M
+ D&A$92.0K
+ Stock-Based Comp$5.3M
+ Deferred Tax$0
- Working Capital-$4.2M
- Other Non-Cash-$22.0M
= Operating Cash Flow-$29.8M
- Capex$0
= Free Cash Flow-$29.8M
Analysis
FY2025 free cash flow is -$29.8M. FCF conversion is 332.1% of net income. Operating cash flow was -$29.8M, with capex of $0. The largest bridge item is Other Non-Cash at -$22.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 425 | 425 filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 425 | 425 filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 6, 2026 |
Does RLYB generate free cash flow?
Rallybio Corporation (RLYB) generated -$29.81M of free cash flow in fiscal 2025.
How much operating cash flow does RLYB produce?
Operating cash flow was -$29.81M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.